The potential of mifepristone (RU-486) as an emergency contraceptive drug

Acta Obstetricia et Gynecologica Scandinavica

Volumn 84, Issue 4, 2005, Pages 309-316

  Sarkar, N N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Abortion; Antiprogestin; Contraception; Endometrium; Pregnancy; Steroid

Indexed keywords

DANAZOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LEVONORGESTREL; MIFEPRISTONE; POSTCOITUS CONTRACEPTIVE AGENT;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; EMERGENCY CONTRACEPTION; FEMALE; HUMAN; IMPLANTATION; MENSTRUATION; NAUSEA; OVULATION INHIBITION; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; SEXUAL INTERCOURSE; VOMITING;

CONTRACEPTIVES, POSTCOITAL, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EMBRYO IMPLANTATION; ENDOMETRIUM; FEMALE; HUMANS; MIFEPRISTONE; TREATMENT OUTCOME;

EID: 16444375054     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2005.00418.x     Document Type: Review

References (47)

1. Sarkar NN. Emergency contraception. Int J Clin Pract 1999; 53: 199-204.
2. Van Look PFA, Von Hertzen H. Emergency contraception. Br Med Bull 1993; 49: 158-70.
3. Spitz IM, Bardin CW. Clinical pharmacology of RU-486: an anti-progestin and anti-glucocorticoid. Contraception 1993; 48: 403-44.
4. Murray S, Muse K. Mifepristone and first-trimester abortion. Clin Obstet Gynecol 1996; 39: 474-85.
5. Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur J Obstet Gynecol Reprod Biol 2002; 101: 113-20.
6. Sarkar NN. The potential of mifepristone (RU-486) as a female contraceptive drug. Int J Clin Pract 2002; 56; 140-4.
7. Van Look P, Bygdeman M. Anti-progestational steroids: a new dimension in fertility regulation. Oxf Rev Reprod Biol 1989; 11: 1-60.
8. Yeng-en S, Zhi-hou Y, Chang-hai H, Guo-qing Z, Jian-qiu X, Van Look P et al. Pharmacokinetic study of RU-486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 1993; 48: 133-49.
9. Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lahteenmaki P. Plasma concentration and receptor binding of RU-486 and its metabolites in human. J Steroid Biochem 1987; 26: 279-84.
10. Sartos O, Figg W. Mifepristone: anti-neoplastic study. Clin Obstet Gynecol 1996; 39: 498-505.
11. Mastroianni L, Coutifaris C, eds. The FIGO manual of human reproduction: reproductive physiology, vol. I. USA: Parthenon Publishing Group, 1990: 1-109.
12. Mayor S. Court rules that emergency contraception is lawful. Br Med J 2002; 324: 995.
13. Psychoyos A, Nikas G, Sarantis I, Gravantis A. Hormonal anti-implantation agents: anti-progestins. Hum Reprod 1995; 10: 140-50.
14. Swahn ML, Danielsson KG, Bygdeman M. Contraception with anti-progesterone. Baillieres Clin Obstet Gynecol 1996; 10: 43-53.
15. Dockery P, Ismail RM, Li TC, Worren MA, Cooke ID. The effect of a single dose of mifepristone (RU-486) on the fine structure of the human endometrium during the early luteal phase. Hum Reprod 1997; 12: 1778-84.
16. Wang JD, Shi WL, Zhang GQ, Bai XM. Tissue and serum levels of steroid hormones and RU486 after administration of mifepristone. Contraception 1994; 49: 245-53.
17. Murphy AA, Kettel LM, Morales AJ, Roberts V, Parmley T, Yen SS. Endometrial effects of long-term low-dose administration of RU486. Fertil Steril 1995; 63: 761-6.
18. Cameron ST, Critchley HO, Thong KJ, Buckley CH, Williams AR, Baird DT. Effects of daily low-dose mifepristone on endometrial maturation and proliferation. Hum Reprod 1996; 11: 2518-26.
19. Ghosh D, Sengupta J, Hendricks AG. Effect of single dose, early luteal phase administration of mifepristone (RU-486) on implantation stage endometrium in the rhesus monkey. Hum Reprod 1996; 11: 2026-35.
20. Danielsson KG, Swahn ML, Bygdeman M. The effect of various doses of mifepristone on endometrial leukaemia inhibitory factor expression in the mid-luteal phase: an immunohistochemical study. Hum Reprod 1997; 12: 1293-7.
21. Cameron ST, Critchley HO, Buckley CH, Kelly RW, Baird DT. Effect of two anti-progestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertil Steril 1997; 67: 1046-53.
22. Marions L, Danielsson KG. Expression of cyclo-oxygenase in human endometrium during the implantation period. Mol Hum Reprod 1999; 5: 961-5.
23. Nayar NR, Sengupta J, Ghosh D. Anti-nidatory effect of luteal phase administration of mifepristone (RU-486) is associated with changes in endometrial prostaglandins during the implantation window. Contraception 1998; 58: 111-17.
24. Norman JE, Wu WX, Kelly RW, Glasier AF, McNeilly AS, Baird DT. Effects of mifepristone in vivo on decidual prostaglandin synthesis and metabolism. Contraception 1991; 44: 89-98.
25. Marions L, Danielsson KG, Bygdeman M. The effect of antiprogestin on integrin expression in human endometrium: an immunohistochemical study. Mol Hum Reprod 1998; 4: 491-5.
26. Durand M, del Carmen Cravioto M, Raymond EG, Duran-Sanchez O, De la Luz Cruz-Hinojosa M, Castell-Rodriguez A et al. On the mechanism of action of short-term levonorgestrel administration in emergency contraception. Contraception 2001; 64: 227-34.
27. Bygdeman M, Danielsson KG, Marions L, Swahn ML. Contraceptive use of anti progesterone. Eur J Contracept Reprod Health Care 1999; 4: 103-7.
28. Marions L, Hultenby K, Lindell I, Sun X, Stabi B, Danielsson KG. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol 2002; 100: 65-71.
29. Trussell J, Ettertson C. Dorflinger L. Effectiveness of the Yuzpe regimen of emergency contraception by cycle day of intercourse: implications for mechanism of action. Contraception 2003; 67: 167-71.
30. Glasier A, Thong KJ, Dewer M, Mackie M, Baird DT. Mifepristone (RU-486) compared with high dose oestrogen and progestogen for emergency post-coital contraception. N Engl J Med 1992; 327: 1041-4.
31. Webb AM, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol and mifepristone (RU-486) in oral post-coital contraception. Br Med J 1992; 305: 927-31.
32. Ashok PW, Stalder C, Wagaarachchi PT, Flett GM, Melvin L, Templeton A. A randomised study comparing low dose of mifepristone and the Yuzpe regimen for emergency contraception. Br J Obstet Gynecol 2002; 109: 553-60.
33. Ashok PW, Wagaarachchi PT, Flett GM, Templeton A. Mifepristone as a late post-coital contraceptive. Hum Reprod 2001; 16: 72-5.
34. Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 1999; 353: 697-702.
35. von Hertzen H, Piaggio G, Ding S, Chen J, Song S, Bartfai G et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception; a WHO multi-centre randomized trial. Lancet 2002; 360: 1803-10.
36. Xiao BL, von Hertzen H, Zhao H, Piaggio G. A randomised double-blind comparison of two single doses of mifepristone for emergency contraception. Hum Reprod 2002; 17: 3084-9.
37. Cheng L, Gulmezoglu AM, Ezcurra E, Van Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev 2000; 2: CD001324.
38. Task Force on Postovulatory Methods of Fertility Regulation. Efficacy and side effects of immediate post-coital levonorgestrel used repeatedly for contraception. Contraception 2000; 61: 303-8.
39. Stirling A, Glasier A. Estimating the efficacy of emergency contraception - how reliable are the data? Contraception 2002; 66: 19-22.
40. Trussell J, Ellertson C, von Hertzen H, Brigigg A, Webb A, Evans M et al. Estimating the effectiveness of emergency contraceptive pills. Contraception 2003; 67: 259-65.
41. Ellertson C, Evans M, Ferden S, Leadbetter C, Spears A, Johnstone K et al. Extending the time limit for starting the Yuzpe regimen of emergency contraception to 120 hours. Obstet Gynaecol 2003; 101: 1168-71.
42. Changhai H, Youlun G, Tie Y, Bingshun W, Exiang Z, Ersheng G et al. A randomised comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception. Contraception 2002; 66: 221-4.
43. Rowlands S, Devalia H, Lawrenson R, Logie J, Ineichen B. Repeated use of hormonal emergency contraception by younger women in UK. Br J Fam Plann 2000; 26: 138-43.
44. Jackson RA, Schwarz ES, Freedman L, Darney P. Advance supply of emergency contraception. Effect on use and usual contraception - a randomised trial. Obstet Gynaecol 2003; 102: 8-16.
45. Ketle H, Cay S, Brown A, Glasier A. Screening for Chlamydia trachomatis infection is indicated for women under 30 using emergency contraception. Contraception 2002; 66: 251-3.
46. Dupont S, Webber J, Dass K, Thornton S. Emergency contraceptive pills (ECP) and sexual risk behaviour. Int J STD AIDS 2002; 13: 482-5.
47. Norris TA, Ellertson C. How safe is emergency contraception? Drug Saf 2002; 25: 695-706.